Zobrazeno 1 - 10
of 182
pro vyhledávání: ''
Autor:
Fadi Braiteh, Dimitrios Chondros, Mark M. Zalupski, Ping Jiang, Andrea Wang-Gillam, Jie Pu, Paul E. Oberstein, W. Wu, Paul S. Ritch, Tara Elisabeth Seery, Sihem Khelifa, Darren Sigal, William P. Harris, Nathan Bahary, Carrie Aldrich, Sunil R. Hingorani, Andrew Eugene Hendifar, Lei Zheng, Andrea J. Bullock
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(4)
Purpose Metastatic pancreatic ductal adenocarcinoma is characterized by excessive hyaluronan (HA) accumulation in the tumor microenvironment, elevating interstitial pressure and impairing perfusion. Preclinical studies demonstrated pegvorhyaluronidas
Autor:
Siraj M. Ali, Joo Hang Kim, Moon Young Choi, Eun Kyung Cho, Hye Ryun Kim, Sun Min Lim, Jin-Haeng Chung, Myung-Ju Ahn, Jong-Seok Lee, Young Joo Min, Sung Sook Lee, Yun-Gyoo Lee, Bong-Seog Kim, Min Jeong Lee, Yoon-La Choi, Byoung Chul Cho, Hyo Sup Shim, Ki Hyeong Lee, Maria Kim
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(23)
Purpose ROS1 rearrangement is a distinct molecular subset of non–small-cell lung cancer (NSCLC). We investigated the efficacy and safety of ceritinib in patients with ROS1-rearranged NSCLC. Patients and Methods We enrolled 32 patients with advanced
Autor:
Keisuke Kosumi, Daniel Nevo, Yan Shi, Mingyang Song, Gordon J. Freeman, Charles S. Fuchs, Kosuke Mima, Yohei Masugi, NaNa Keum, Zhi Rong Qian, Marios Giannakis, Shuji Ogino, Jonathan A. Nowak, Jeffrey A. Meyerhardt, Wanwan Li, Reiko Nishihara, Andrew T. Chan, Yin Cao, Juhong Yang, Mancang Gu, Scott J. Rodig, Edward Giovannucci, Li Liu, Kana Wu, Tsuyoshi Hamada, Xuehong Zhang, Annacarolina da Silva, Molin Wang
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(16)
Purpose Blockade of the programmed cell death 1 (PDCD1, PD-1) immune checkpoint pathway can improve clinical outcomes in various malignancies. Evidence suggests that aspirin (a widely used nonsteroidal anti-inflammatory drug) not only prolongs colore
Autor:
Kathleen N. Moore, Raymond P. Perez, David M. O'Malley, Lainie P. Martin, Michael J. Birrer, Todd M. Bauer, Jason A. Konner, Rodrigo Ruiz-Soto, Ursula A. Matulonis
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(10)
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody–drug conjugate consisting of a humanized anti–folate receptor alpha (FRα) monoclonal antibody linked to th
Autor:
Kala Visvanathan, Catherine Pesce, Bradley M. Turner, Lorraine Tafra, Stacie Jeter, David G. Hicks, Leslie Cope, Maria Cristina Figueroa-Magalhães, Ashley Cimino-Mathews, Charles Mylander, Deborah K. Armstrong, Dylan V. Miller, Tyler A. Jensen, Robert S. Miller, Vered Stearns, Hyun-Seok Kim, Martin Rosman, Christopher B. Umbricht, Antonio C. Wolff, Ben Ho Park, John H. Fetting, Roisin M. Connolly, Peter B. Illei, Soonweng Cho, Nivedita Chowdhury
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(36)
Purpose Gene expression profiling assays are frequently used to guide adjuvant chemotherapy decisions in hormone receptor–positive, lymph node–negative breast cancer. We hypothesized that the clinical value of these new tools would be more fully
Autor:
Adil Daud, Richard W. Joseph, Xiaoyun Nicole Li, Marisa Dolled-Filhart, Amita Patnaik, Grant Toland, Roxana S. Dronca, Wen-Jen Hwu, Charlotte Roach, Tara C. Gangadhar, Caroline Robert, Omid Hamid, Richard F. Kefford, Antoni Ribas, S. Peter Kang, Scot Ebbinghaus, Peter Hersey, Hassane M. Zarour, Anthony M. Joshua, Jared Lunceford, F. Stephen Hodi, Jedd D. Wolchok, Kenneth Emancipator, Jeffrey S. Weber
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 34, iss 34
Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti–programmed death 1 (PD-1). This study explored the relationship between anti–PD-1 activity and PD-L1 expre
Autor:
Dennis J. Slamon, Guy Jerusalem, David Chen, Ruth O'Regan, Fabrice Andre, Claudine Isaacs, Douglas Robinson, Sara A. Hurvitz, Howard A. Burris, Sharon Wilks, Tetiana Taran, Ling-Ming Tseng, Angelica Fasolo, Markus Riester, Masakazu Toi, Wei He
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(18)
Purpose Two recent phase III trials, BOLERO-1 and BOLERO-3 (Breast Cancer Trials of Oral Everolimus), evaluated the addition of everolimus to trastuzumab and chemotherapy in human epidermal growth factor receptor 2–overexpressing advanced breast ca
Autor:
Michael F. Berger, David B. Solit, Mark E. Robson, Leonard B. Saltz, Rona Yaeger, Sumit Middha, Nancy E. Kemeny, Jinru Shia, Julio Garcia-Aguilar, Martin R. Weiser, Francesca Battaglin, Maria E. Arcila, Andrea Cercek, Christina Tran, Asad Ashraf, Erin E. Salo-Mullen, Neil H. Segal, Zsofia K. Stadler, Diane Reidy-Lagunes, Kenneth Offit, Anna M. Varghese, Jaclyn F. Hechtman
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(18)
Purpose Tumor screening for Lynch syndrome is recommended in all or most patients with colorectal cancer (CRC). In metastatic CRC, sequencing of RAS/BRAF is necessary to guide clinical management. We hypothesized that a next-generation sequencing (NG
Autor:
Jean Richard Saint-Martin, Richard D. Kim, Thaddeus J. Unger, Nashat Y. Gabrail, Ulrik Lassen, Dilara McCauley, Amit Mahipal, Albiruni Ryan Abdul Razak, Tami Rashal, Yosef Landesman, Anthony F. Shields, Mansoor Raza Mirza, Michael Kauffman, Lee Anne Stayner, John F. Gerecitano, Sharon Shacham, Morten Mau-Soerensen, Robert W. Carlson
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(34)
Purpose This trial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a novel, oral small-molecule inhibitor of exportin 1 (XPO1/CRM1), and determined the recommended phase II dose. Patients and Methods In
Autor:
Stephan Stilgenbauer, Andreas Rosenwald, Christoph Loddenkemper, Olivier Hermine, Bertrand Coiffier, Catherine Thieblemont, Johanna Kluin-Nelemans, Wolfgang Hiddemann, Christian Schmidt, Michael Hallek, Michael Pfreundschuh, Françoise Berger, Heinz-Wolfram Bernd, Roswitha Forstpointner, Reda Bouabdallah, Wolfram Klapper, Eva Hoster, Roman Kodet, Lothar Kanz, Nicole Brousse, Martin Dreyling, Thomas F. E. Barth, Sylvia Hartmann, Ursula Vehling-Kaiser, Michael Unterhalt, Vincent Ribrag, Stefano Pileri, Grzegorz Rymkiewicz
Publikováno v:
Journal of Clinical Oncology, 34(12), 1386-1395. AMER SOC CLINICAL ONCOLOGY
Purpose Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose considerable variability of individual outcome is associated with clinical characteristics (Mantle Cell Lymphoma International Prognostic Index [MIPI]). The Ki-67 index